

This version of the article has been accepted for publication, after peer review and is subject to [Springer Nature's AM terms of use](#), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: <https://doi.org/10.1038/s43016-020-0112-z>

1 **The status of cultured meat and scientific challenges**

2

3 Mark J Post<sup>1,7</sup>, Shulamit Levenberg<sup>2</sup>, David L Kaplan<sup>3</sup>, Nicholas Genovese<sup>4</sup>, Jianan Fu<sup>5</sup>,

4 Christopher J Bryant<sup>6</sup>, Panagiota Moutsatsou<sup>7</sup>

5

6 1) Maastricht University, Department of Physiology, CARIM, Maastricht, The Netherlands

7 2) Technion, Department of Biomedical Engineering, Israel Institute of Technology, Haifa,

8 Israel

9 3) Tufts University, Department of Biomedical Engineering, Boston, USA

10 4) Memphis Meat, California

11 5) PAN-Biotech LTd, Aidenbach, Germany

12 6) University of Bath, UK

13 7) Mosa Meat B.V., Maastricht, The Netherlands

14

15

16 Corresponding author:

17 Mark J Post, MD, PhD

18 Department of Physiology, Maastricht University

19 Universiteitssingel 50, 6229 ER, Maastricht, the Netherlands

20 [m.post@maastrichtuniversity.nl](mailto:m.post@maastrichtuniversity.nl)

21 tel +31 43 3881200

22

23

## 24 **Abstract**

25 Cellular agriculture is an emerging branch of biotechnology aiming to tackle the issues  
26 associated with conventional industrial animal farming for meat production, i.e.  
27 environmental impact, controversial animal welfare and unsustainability. Cultured meat can  
28 be produced by applying current cell culture practices and bio-manufacturing methods that  
29 are already being used for the production of biologics, utilizing mammalian cell lines and the  
30 production of cell and gene therapy products to produce tissue or nutritional proteins.  
31 However, to bring production at scale, significant improvements and modifications need to  
32 take place for such a process to be cost efficient and robust enough to serve for food supply.  
33 The present study looks at the different scientific aspects to be tackled in order to render  
34 cultured meat into a viable commercial option. It is an interdisciplinary endeavor covering  
35 aspects from cell selection and medium optimization to biomaterials and tissue engineering.  
36 The current status of each of these fields is documented together with expert insight of what  
37 are the remaining challenges to be addressed as well as their potential respective solutions.

38

## 39 **Why culturing meat?**

40 The promise of cultured meat rests largely upon resolution of the problems related to  
41 industrial livestock farming, thereby circumventing some of its undesirable consequences <sup>1</sup>.  
42 The IPCC (2018) has stated that we need to substantially reduce our consumption of  
43 conventional animal products to avoid the worst effects of climate change, yet most  
44 consumers are not willing to do this <sup>2</sup>. Harnessing the potential of stem cells to multiply and  
45 form skeletal muscle and fat tissue allows a vast reduction in livestock necessary to produce  
46 meat. Advantages of cultured meat broadly fall into three categories: sustainability, animal  
47 welfare, and public health.

48

49 In terms of greenhouse gas emissions, water consumption, and land use, cultured meat is  
50 far more efficient than conventional meat <sup>3-5</sup>. Studies have, however, found that cultured  
51 meat might be more energy-intensive <sup>3,5</sup>, and therefore some environmental benefits are  
52 dependent on a transition to clean energy sources <sup>6</sup>.

53

54 Second, cultured meat presents incontestable advantages in terms of animal welfare <sup>7</sup>. The  
55 Sentience Institute (2019) estimates that 99% of animals used for food are factory farmed,  
56 and are therefore considered industrial products rather than sentient beings <sup>8</sup>.

57

58 Third, there are substantial public health benefits from cultured meat production.

59 Conventional meat is the most common food source of potentially fatal infections such as  
60 salmonella and listeria (Painter, 2013). The production process of cultured meat guarantees  
61 the absence of contaminants during cultivation and can also be realised without the use of  
62 antibiotics. Antibiotic abuse in agriculture is a large problem contributing to antimicrobial  
63 resistance in pathogens which affect humans <sup>9,10</sup>.

64


65 Finally, the resource intensity of livestock meat production requires an estimated 70% of  
66 our arable land to be used for the purpose of feeding livestock <sup>11</sup>. With an anticipated 70%  
67 increase in global meat demand, in 2050 we will have insufficient planetary resources to  
68 provide meat to the world population.

69

## 70 **What is cultured meat?**

71 Cultured meat aims to copy conventionally produced meat, through (stem)cell and tissue  
72 culture. The idea to use cell and tissue culture to produce meat is old, with first references  
73 in utopian literature from the 19th century <sup>12</sup>. The discovery of stem cells made *in-vitro* cell  
74 production possible and opened the road to cultured meat. Stem cells can be isolated from

75 a simple biopsy from a living animal <sup>13</sup> and then expanded *in-vitro* to generate a large  
76 number of cells. Subsequently, the cells can be stimulated to differentiate into muscle or fat  
77 cells, depending on the isolated stem cell type. Tissue engineering techniques, typically  
78 involving a biomaterial scaffold that gives temporary or permanent support and 3D  
79 organization of the cells, lead to the assembly of a tissue that resembles meat in its sensory  
80 and nutritional qualities as closely as possible. In theory, one can approach mimicry of meat  
81 in different ways, ranging from single protein production of individual muscle proteins to  
82 fully fledged tissue engineering of a complex muscle tissue containing muscle, fat, blood  
83 vessels, nerves, fibrous tissue and perhaps resident immune cells, in a natural architecture  
84 (Figure 1). The generation and assembly of multicellular muscle fibers and fat organoids into  
85 a minced meat product lies in between these extremes. This review focuses mostly on tissue  
86 engineered meat as this method is most commonly employed by investigators and startup  
87 companies, because it is scientifically the most comprehensive and enables the production  
88 of a meat copy. It means that at the very least the final product contains mature muscle  
89 fibers.



90

91 Fig 1. Principle of cultured meat. Stem cells are harvested from mature muscle tissue and

92 expanded to large numbers. Using a gel biomaterial and a specific differentiation protocol

93 (2% growth factor medium for muscle and free fatty acids for adipose tissue derived stem  
94 cells), mature muscle fibers and pieces of adipose tissue are being formed.

95

96 Originally coined as 'in vitro meat' because the cells and tissue are cultured in vitro, the  
97 name of cultured meat is still a subject of debate. Currently, cultivated meat, cultured meat,  
98 cell-based meat and clean meat are the most prevalent names. Although some of the  
99 institutions represented by the authors favor a different name, for the purpose of this  
100 review we use the term cultured meat as a descriptor. Culturing meat is part of a proposed  
101 novel industry referred to as cellular agriculture, i.e. using cell-based biotechnology to  
102 replace traditional animal derived products such as meat, seafood, leather and milk. These  
103 endeavors have a common aim to reduce the negative societal impact of traditional  
104 livestock agriculture, while maintaining its widely acknowledged nutritional and cultural  
105 value.

106

#### 107 **Cell selection**

108 A cultured meat bio-manufacturing process begins with one or more starting cell populations.  
109 The starting cell population may be homogeneous or exhibit various levels of heterogeneity.  
110 Although meat is a complex tissue, the current notion is that species specific skeletal muscle  
111 cells and adipocytes are the minimal necessary components of cultured meat. The suitability  
112 of the starting cells for manufacturing, is based upon their capacity for self-renewal and  
113 differentiation, in an environment where other animal components are minimized or  
114 eliminated.

115 Self-renewal is defined by a cell's continued ability to replicate and expand in numbers, while  
116 retaining its potential to differentiate in one or more tissue lineages. Stem cells such as  
117 embryonic stem cells (ESCs) can differentiate into any tissue and are known as pluripotent  
118 stem cells <sup>14</sup>. During embryonic development these ESCs give rise to progeny that becomes

119 more committed and loses pluripotency. For instance, so called mesenchymal stem cells  
120 (MSCs) have limited differentiation capacity but can still form bone, cartilage and adipose  
121 tissue. The progeny cells can remain quiescent in tissues as an adult stem cell, or can  
122 contribute to a developing or regenerating tissue as a transit amplifying cell <sup>15</sup>, in a process  
123 called asymmetric division. Amplifying cells proliferate fast and extensively prior to  
124 differentiating terminally into post-mitotic cells that form most mature functional tissues. They  
125 present though a limited replicative capacity (i.e. amount of cell doublings they can undergo).  
126 Implementation of cells from various stages of stem cells has been proposed for cultured  
127 meat manufacturing <sup>16,17</sup>. Here, the suitability of a given stem-cell type for meat production,  
128 will be evaluated with respect to their capacity to expand and differentiate into skeletal  
129 muscle, the predominant constituent of most meats. Similar considerations however apply to  
130 the adipocyte lineage.

131         Adult stem cells of skeletal muscle, also known as satellite cells, constitute the most  
132 accessible myogenic progenitor in skeletal muscle tissues, and require little coaxing to  
133 differentiate into skeletal myotubes. It is these satellite cells, or rather their amplifying  
134 progeny called myoblasts, that were used to create the first cultured meat hamburger  
135 prototype <sup>13</sup>. Myoblasts propagate rapidly and egress from the cell-cycle as spindle-shaped  
136 myocytes that fuse with multinucleated myofibers during tissue repair and development <sup>18</sup>.  
137 Satellite cells and especially myoblasts require substantial optimization to increase their  
138 proliferative capacity for adaptation to industrial-scale cultured meat manufacturing  
139 applications <sup>19</sup>.

140

141         A primary consideration when isolating satellite cells for applications in cultured meat  
142 production is the muscle of origin. Skeletal muscle fiber types are broadly designated as  
143 oxidative slow-twitch, and glycolytic fast-twitch, respectively recognized as red and white  
144 meat. *In-vitro* porcine studies suggest that satellite cells retain the character from their  
145 originating tissue <sup>20</sup>. Additionally, purification of the starting satellite cell population from the

146 biopsy material can be performed relatively simply by differential adhesion protocols or by  
147 fluorescence activated cell sorting (FACS) based on biomarker characteristics <sup>21-24</sup>. Industrial  
148 manufacturing of cultured meat at a scale sufficient to satisfy commercial demand heavily  
149 relies on cell propagation, starting in small planar culture system and gradually moving to  
150 large bioreactors <sup>25,26</sup>. As transient amplifying cells however, myoblasts can undergo a finite  
151 number of doublings and gradually lose their differentiation capacity. Therefore, efficient  
152 biomanufacturing could benefit from retaining satellite cells in their stem cell stage with  
153 presumably indefinite renewal capacity, while still being able to produce myoblasts. A recent  
154 study <sup>21</sup> demonstrated that this renewal can be extended *in-vitro* by inhibiting a cell signaling  
155 pathway known as p38-MAPK. Upon withdrawal of this inhibition, satellite cells retain their  
156 differentiation capacity. Similar interventions might lead to a more efficient use of satellite  
157 cells taken from a single biopsy.

158

159 Functional immortalization may provide another approach to extend the replicative capacity  
160 of skeletal muscle cells for industrial-scale expansion. For over four decades, differentiation  
161 competent, immortalized skeletal muscle cell lines have served as model systems in skeletal  
162 muscle biology research. Isolated from rat <sup>27</sup> or mouse <sup>28</sup> model organisms and  
163 spontaneously derived through consecutive passaging, these cell lines lack the species  
164 identity culturally acceptable for producing meat for human consumption <sup>7</sup>. Though a  
165 myogenic quail cell line has been described, the ability of this cell line to form mature  
166 myofibers is severely impaired <sup>29</sup>. Targeted genetic approaches developed for functional  
167 immortalization of human skeletal muscle cells <sup>30</sup> may provide alternative pluripotent cell  
168 lines from traditional livestock species for industrial biomanufacturing of cultured meat <sup>31</sup>.  
169 Unlike satellite cells, these so-called induced pluripotent stem cells (iPSCs) have an  
170 indefinite renewal capacity, because their early commitment to specific tissue lineages is  
171 inhibited. iPSCs are derived by reprogramming cells isolated from somatic tissues to the  
172 pluripotent state by directed expression of a combination of transcription factors often

173 including POU5F1, SOX2, KLF4 and MYC <sup>32</sup>. Human and mouse models have constituted  
174 most of the research and development reported on pluripotent stem cells to date, thus these  
175 findings still need to be translated to livestock species <sup>7</sup>.  
176 ESCs and iPSCs from agriculturally relevant ungulate species, such as pigs and cows, have  
177 only recently been derived successfully and characterized <sup>33-36</sup>, while the derivation of bona  
178 fide ESCs or iPSCs from avian species, namely chicken, remains elusive. Established  
179 culture conditions have been unable to support stable, long-term culture of pluripotent cells  
180 derived from the avian blastoderm, and attempts of deriving iPSCs have resulted in partially  
181 reprogrammed cell lines <sup>37</sup>.  
182 Protocols established for differentiating pluripotent stem cells to skeletal muscle have taken  
183 alternate approaches with varied results. One approach relies upon culture regimens of  
184 growth factors and small molecule inhibitors to direct cells from the pluripotent state toward  
185 the myogenic lineage <sup>38</sup>, whereas an alternate approach employs conditional activation of  
186 ectopically expressed transcription factors for programming cells to a myogenic lineage from  
187 a progenitor state. The later approach is reported to derive myogenic cells and direct their  
188 differentiation in a more efficient manner <sup>39</sup>. In fact, a variation of this programming approach  
189 was previously demonstrated in a porcine iPSC model resulting in contractile myotubes <sup>40</sup>.  
190 There is a strong precedent established for derivation and maintenance of pluripotent stem  
191 cells in serum-free <sup>41,42</sup>, and animal component free cell culture medium <sup>43</sup>, as well as  
192 cultivation of these cells in a carrier-free suspension environment <sup>44,45</sup>, features that would  
193 greatly facilitate industrial scale production.  
194 Both the advancements in the maintenance of adult stem cells and the derivation of bona  
195 fide ungulate pluripotent stem cell lines opens up distinct yet promising avenues for  
196 manufacturing cultured meat. With technologies for production of cultured meat rapidly  
197 evolving, it is likely that multiple stem cell paradigms will find applications in industrial  
198 manufacturing based upon the advantages inherent to their respective biology.

199

## 200 **Medium**

201 Cells are cultured in a nutritious and oxygenated fluid which traditionally is referred to as  
202 'medium'. As a result of the projected scale of cultured meat production, resource efficiency  
203 (feedstock, water and power usage), scalability of production and cost are critical boundary  
204 conditions. The cost of cell culture medium has been identified as one of the major cost  
205 drivers during upscaling of stem cell production <sup>46</sup>.

206 The fundamentals of designing a good cell culture medium is qualitative and quantitative  
207 understanding of the physiology and metabolism of the target cell. Metabolism is regulated  
208 at cellular, molecular and genetic levels with different allosteric reaction rates. The  
209 availability and concentration of the substrates in cell culture media are obvious key  
210 parameters <sup>47</sup> in optimizing the overall yield of the metabolic reaction network towards a  
211 more efficient biomass production. Mammalian cells usually show inefficient consumption  
212 of carbon, nitrogen and energy sources and overproduction of metabolic byproducts such as  
213 lactate and ammonium <sup>48</sup>. There are two approaches to increase the metabolic efficiency.  
214 One is to use fed-batch or perfusion processes, which has been shown to increase cell  
215 density 3.4-fold <sup>49</sup> and result in a more effective metabolism, perhaps due to lower  
216 concentration fluctuations of substrate or metabolites. The other is metabolic engineering  
217 where the composition of the medium is optimized to drive metabolic pathways. The latter  
218 has been successful in optimizing medium for cell lines to produce pharmaceutical products  
219 50-52 .

220 Besides productivity, the composition of cell culture media will also define the final  
221 characteristics of the cultured meat product. In the livestock industry factors such as  
222 climate, nutrition and stress define the meat product. For example, it has been suggested  
223 that acidosis caused by rapid glycolysis leads to degenerative changes in muscle fibers,  
224 which are solitary and rich in type II fibers <sup>53-55</sup>. Affected muscles show undesired

225 characteristics such as being pale, soft and exudative (PSE) <sup>56</sup>. In cell culture, an even more  
226 direct influence on cellular metabolism and resulting cultured meat characteristics by the  
227 medium is likely. In highly proliferating cells it has been shown that over 70% of the glucose  
228 is metabolized to lactate with associated acidosis, leaving only 20 to 30 % of the glucose  
229 entering the TCA cycle <sup>57</sup>. Nutritional deficiencies, such as lack of vitamins, cause  
230 degenerative changes in muscle, as indicated in the case of vitamin D <sup>58</sup>, vitamin E and  
231 selenium <sup>56</sup>.

232  
233 Medium for proliferating cells need to be different than for differentiating cells as  
234 metabolism changes from primarily energy and general nutrient usage to highly specialized  
235 protein production. With more complex tissues that are composed of muscle and fat tissue  
236 for instance, again different media compositions will be required.

237  
238 Cell culture medium is not only important for productivity and quality, it also contributes to  
239 the sustainability of the overall process. Animal derived components, including serum,  
240 cannot be part of the medium, because they introduce contamination risks and undefined  
241 substances and violate the ethical principle of using less animals, but most importantly, they  
242 are unsustainable. Cell culture medium, where serum is replaced by proteins, growth  
243 factors, sugars and fatty acids that take over the function of serum needs to be chemically  
244 defined. Components that need to be present in high concentrations, such as glucose and  
245 amino acids, will have a strong impact on the environmental footprint of the process. Today,  
246 amino acids, the building blocks for protein synthesis and thus very important for meat  
247 production, are most effectively produced through fermentation <sup>59</sup>, using mainly glucose as  
248 substrate. The industrial production of glucose is well established, with little waste  
249 production and a high level of integration: 57% of the electricity and 59% of the heat input

250 are produced by a combined heat and power (CHP) system<sup>60</sup>. It is based on hydrolysis of a  
251 raw material such as starch which is naturally produced by plants through photosynthesis  
252 and therefore requires the use of land and water.

253 To achieve media with the lowest footprint, ingredients need to be sourced and dosed  
254 judiciously. As an example, from an environmental perspective, glutamine should be  
255 avoided to be used as an energy source instead of glucose, . Also, alternative sources of  
256 amino acids and peptides should be evaluated, such as biomass from algae and certain  
257 bacterial cultures. These microorganisms not only provide cheap sources of enriched amino  
258 acids, fats, vitamins and minerals, but also offer opportunities to couple the cultured meat  
259 production with other sustainable processes like waste treatment or CO<sub>2</sub> capture<sup>5,61-65</sup>.  
260 Furthermore, recycling of culture media has been increasingly investigated for cell culture  
261 processes due to potential economic and ecological advantages. This strategy has been  
262 successfully demonstrated in bacterial and algae cultures with promising results with  
263 respect to cost reduction and extended batch duration<sup>66-68</sup>. In combination with perfusion,  
264 this strategy could be particularly interesting for the cultured meat process, as it would  
265 significantly minimize the use of sterile, purified water, which is energy intensive. However  
266 medium recycling has not yet been applied to mammalian cell cultures.

267

268 Metabolic engineering will increasingly rely on constraint-based modeling and flux balance  
269 analysis that have been widely applied to predict and quantify the metabolic state of cells  
270<sup>69,70</sup>. Multi-omic flux balance analysis can help to predict flux distributions in a more reliable  
271 way based on limited experimental data due to comprehensive crosslink of multiple omics  
272<sup>71</sup>. Metabolic modeling will be a powerful tool to predict not only the functional state of  
273 cells, but also optimal nutrient formulations for cell growth *in vitro*. In the future, more  
274 efforts are necessary towards the study of interactions between genome and metabolites

275 using association mappings<sup>72</sup>, in order to improve objective and comprehensive function  
276 (not only growth maximization) for modeling<sup>73-77</sup>. However, to effectively validate and  
277 employ these methods, quantitative information on metabolic pathways and deep  
278 knowledge of the effect of a huge number of medium components and of their synergies  
279 are required. To add complexity, this input will likely be species and cell type specific. In  
280 such a multi-variable field of research, it is to be expected that metabolic modelling fed and  
281 validated by large amounts of data is required to support the experimental work

282

### 283 **Scaling up, bioreactors, automation**

284 For cultured meat to become a viable alternative to traditional meat, production has to be  
285 scalable and economical, factors typically going hand in hand. The specifics of scaling  
286 depend on the final intended product and the number of doublings the stem cell can  
287 sustain. For a minced product, the scaling is different than for a full thickness meat product.  
288 This is primarily true for the final stage, i.e. the organoid or tissue production, but the cell  
289 production will likely be similar as long as the cell production and tissue production phase  
290 are separated.

291 The objective of cell production is through a seeding train and a set of bioreactors of  
292 increasing volume, to generate a maximum number of cells while minimizing the needed  
293 feedstock, materials and culture manipulations. The seeding train is used to expand from  
294 the initial harvest number, which is typically in the order of  $10^3$  cells to the desired batch  
295 amount, in the range of  $10^{13}$  cells, to create 1 ton of cultured meat (muscle). Seeding train  
296 optimization is focused towards maintaining the cells at the phase of exponential growth,  
297 while preventing them from differentiating early, and is highly dependent on the cell type  
298 78,79. Therefore, the initial culture is performed in regular culture dishes or flasks, and as cell  
299 number grows, the culture is gradually moved to bioreactors with controlled conditions such

300 as temperature, pH and dissolved oxygen and carbon dioxide. The industry standard for  
301 mammalian cell culture in bioreactors is a stirred tank bioreactor where cells are either in  
302 suspension or attached to microcarriers that are suspended in the agitated medium <sup>80</sup>. Cell  
303 suspension is beneficial because of higher achievable cell densities and ease of harvesting.  
304 However, most mammalian cells are anchorage dependent, meaning that they have to  
305 attach to a surface, hence the advent of microcarriers that, while suspended, provide  
306 surface for the cells to grow. Similar to mesenchymal stem cells, bovine myoblasts can be  
307 expanded on microcarriers in suspension <sup>81</sup>.  
308 Recent developments show some success in modifying induced pluripotent stem cells  
309 (iPSCs) so that they can grow in aggregates <sup>44,82</sup>, very similar to earlier achievements in  
310 embryonic stem cells (ESCs) from mice <sup>83</sup> and human <sup>84,85</sup>. More committed stem cells such  
311 as mesenchymal stem cells, can form aggregates and grow, but the aggregate size is hard to  
312 control <sup>86</sup>, leading to unpredictable cell yield. No large-scale cell culture data using  
313 aggregates is available. Cells from the C2C12 myoblast line can also form aggregates, but  
314 here too, no data is available on suspension culture in aggregates. It is anticipated that  
315 aggregate culture of MSCs or myoblasts is more challenging because of their tendency to  
316 differentiate in a 3D environment.


317

### 318 *Bioreactors*

319

320 For the large-scale production of cells required to produce cultured meat, bioreactors are  
321 the preferred culture modality because of their scalability, controllability and higher  
322 achieved cell densities than planar systems can offer <sup>87,88</sup>. Experience with large scale cell  
323 culture of anchorage dependent mammalian cells is being developed mostly for the MSC  
324 cell therapy field <sup>89</sup>.

325 The most commonly used bioreactors are stirred tanks and rocking bioreactors (also known  
326 as wave bioreactor). Alternate bioreactor configurations include perfused packed bed  
327 reactors, plug flow reactors such as hollow fibre, air-lift, vertical wheel and fluidized bed  
328 bioreactors but also novel modes of operation of the stirred tank and rocking bioreactor  
329 25,90. In Figure 2, the schematics of these bioreactors are presented. The ultimate goal of  
330 these developments is to increase the medium conversion ratio, i.e. the percentage of  
331 nutrients in the medium that is converted to edible animal tissue, equivalent to the feed  
332 conversion in traditional livestock meat production. The most important levers to improve  
333 the medium conversion ratio are cell density (cell number/ml medium) and optimal use of  
334 medium through recycling techniques. A second, equally important, goal is to scale up cell  
335 production to achieve cost-effectiveness. In addition to the production of cells, tissues need  
336 to be formed by the cells. In the absence of a fully integrated system where cells can not  
337 only divide, but also mature as a tissue after (self) assembly, the tissue formation stage  
338 occurs in a different bioreactor that is optimally suited to condition the forming tissue. Here,  
339 the diversity in reactor designs will be even bigger depending on the type of tissue to be  
340 formed and its specific conditioning needs. The labor-intensive parts of the process will  
341 need to be automated to reduce cost, and perhaps even more important, the risk of  
342 microbial contamination.  
343



344

345 Figure 2: Most common bioreactor designs for mammalian cell culture. A: stirred tank; B:  
 346 airlift; C: wave; D: flow through, E: hollow fibre.

347

348 Bioprocess development and optimization is also key to bring down production costs. *In*

349 *silico* modelling of cell behavior will play a pivotal role in the next years, as to realize

350 consistent production at scale, especially when the source material is primary cells,

351 significant efforts need to be made to shift away from the current semi-scaled up systems

352 and the “trial and error” upscaling approaches that currently dominate the field of cell &

353 gene therapy 91,92.

354

355 Finally, the manufacturing process does not only include cell and tissue production, but also

356 harvesting and purification of cells after production, cell storage, banking and transport,

357 standardization and traceability of tissue harvest from animal donors, quality control of the

358 produced tissues and regular food technology to process those into meat products.

359

## 360 **Biomaterials**

361 Biomaterial scaffolding is a key component to cellular agriculture, providing numerous  
362 functions to support cells towards tissue formation. Scaffold serves as an integrating support  
363 network onto and into which cells expand, differentiate and exploit their anchorage-  
364 dependent needs for survival and functions. Scaffolds also provide the porous network  
365 through which oxygen and nutrients flow and waste products are removed, thus maintaining  
366 cell metabolic functions and avoiding necrotic cores over time. To serve these purposes, a  
367 balance between morphology, structure and chemistry is required. Historically, scaffolding  
368 from biomaterials have focused on medically-relevant outcomes, for the fields of tissue  
369 engineering and regenerative medicine<sup>93-97</sup>. For such goals, the scaffold requirements are  
370 in part, different and more stringent than in the case of scaffolds utilized for cellular  
371 agriculture in foods (**Table 1**).

372 Scaffolding is usually degradable, but if it is not, it has to be edible in uncooked or cooked  
373 conditions. Edible and regulation-compatible scaffold material for food tissue engineering  
374 has to achieve physical goals such as texture, taste and thermal stability related to  
375 consumption, cooking and nutrition. It also has to be cheap and sourceable at large scale.

376 Biomaterial Scaffold Options – A variety of biomaterial scaffolds are being pursued for  
377 cellular agriculture, most of which are derived from biological sources but processed for  
378 desired structure and morphology, while retaining native chemistry (**Table 1**). To reduce  
379 cost, manipulation of the biologically sourced material should be kept at a minimum.

380 Products derived from traditional livestock animals such as collagen are to be avoided since  
381 they are non-replicative and would therefore still require a substantial production of livestock  
382 for production. Thus, more promising materials are polysaccharides such as cellulose, starch  
383 (amylose/amylopectin), chitin/chitosan, pullulan, alginates, hyaluronic acid, and others<sup>98</sup>.

384 Protein-based systems include fibrin, collagen/gelatin, keratin, or silk, where the materials  
385 are sourced through recombinant technology. Other materials of interest include the family of  
386 polyesters, polyhydroxyalkanoates, expressed in bacteria and other systems<sup>99</sup>. Finally,  
387 complex composite matrices generated from plants and microorganisms are also actively

388 pursued, including lignins, plant matrices (e.g., decellularized leaves), fungal mycelia and  
389 others <sup>100</sup>. Aside from biopolymers, there are a number of synthetic polymers that can be  
390 considered, including a range of polyesters. Generally, these systems are safe in the human  
391 body and can have a tailored degradation rate via chemical hydrolysis [REF]. Benefits of  
392 synthetic polymer systems are consistent quality and supply, but cost and requirement for  
393 surface functionalization may be limiting.

394 Testing and Methodology Considerations – Well-established methods to study morphology,  
395 structure and chemistry can be pursued for the characterization of these materials including  
396 SEM, AFM, TEM, X-ray, FTIR, elemental analysis and rheological assessments (Table 2).  
397 However, the additional unique features for scaffolds related to cellular agriculture, include  
398 aspects of texture, digestion, cook-loss, water-binding capacity and taste that are less  
399 commonly considered in medically-related scaffold designs. Each of these features must be  
400 assessed with appropriate methods to ensure compatibility for human consumption as part  
401 of foods. For example, nutritional analyses, including extraction and chromatographic  
402 quantitation of key nutrients, mechanical testing to assess texture (e.g., Warner-Bratzler  
403 shear force, water-holding capacity and cook-loss from the meat industry), and nutritional  
404 safety need to be considered.

405 Additional Considerations - Additional factors to be considered for cultured meat applications  
406 include degradation lifetime *in vitro* and during digestion. This is preferably established with  
407 *in vitro* screening simulating the gastrointestinal conditions (pH, mechanics and digestive  
408 enzymes). Such screens would be performed on both pre- and post-thermally modified  
409 'cooked' versions of the scaffolds to compare outcomes, similar to testing of other novel food  
410 ingredients <sup>101</sup>.

411 Ultimately, cost of scaffolds used in culturing meat is an overriding issue to consider where  
412 scaffolds should be a small component of the total costs. Key to minimize cost of goods and  
413 to guarantee consistency is production of those materials at large scale. Many of the  
414 polymers on Table 1 are already being produced at scale.

415

416 **Table 1.** Some polymer options for scaffolds for cellular agriculture via non-animal sourcing.  
 417 There is insufficient data to date to ascribe these scaffold polymers to specific food tissue  
 418 engineering outcomes.

<b>Biopolymer Class</b>	<b>Specific Type</b>	<b>Source, features</b>
polysaccharides	Cellulose and its derivatives (CMC, HPMC, MC)	plants, bacteria
	starch (amylose, amylopectin)	plants
	chitin/chitosan	crustaceans, insects, fungi, yeast
	hyaluronic acid, methacrylate derivatives	heterologous expression
	alginate	plants
	agarose	plants
proteins	collagen/gelatin, zein, methacrylate derivatives	heterologous expression
	silk	silkworms, spiders, heterologous expression
	elastin	heterologous expression
	keratin	heterologous expression
	Laminin	Heterologous expression
polyesters (PHAs)	polyhydroxyalkanoates (and variants of homopolymers, copolymers)	heterologous expression
synthetics	polylactic/polyglycol acids	chemical synthesis

	polycaprolactone	chemical synthesis
	polyethylene glycol	chemical synthesis
	polyvinylalcohol	chemical synthesis
complex natural composites	mycelia	fungi
	lignin	plants
	decellularized tissues	plants

419

420 **Table 2.** Scaffold design features (physical, chemical, biological considerations) for biomaterials to be

421 considered in cellular agriculture applications.

Property	Features to consider	Analyses
<b><i>Physical</i></b>		
Processability, structure, thermal stability (cooking)	Rheology, flow behavior, thermal stability, changes in structure with temperature	Viscometer, rheometry, dynamic mechanical analysis, differential calorimetry, thermal gravimetric analysis
Architecture, Texture	Crystallinity, porosity, content	Instron compression testing, XRD, FTIR, Warner-Bratzler Shear Force
Surface Features	Chemistry, functionalization	Immunohistochemistry, NMR
Morphology	Fiber size, surface topography, porosity, alignment, manufacturing approaches	SEM, mercury porosimetry, histology; fibers (extrusion, electrospinning), films (casting, rolling), sponges (porogens, gas evolution, freeze fronts for alignment), hydrogels (self-assembly, covalent crosslinks, selective chemistry)

		3D printing
<b>Chemical</b>		
Edible/digestibility/stability	Polymer chemistry, enzymes, chemical hydrolysis	In vitro mimetic solutions (enzymes – proteases, oxidases, hydrolases; chemical composition, gut/saliva simulants, pH, bile, etc.), macrophage screens, LPS assays, endotoxin screens, chemical screens for residuals (e.g., antibiotics, endocrine mimics, etc.)
<b>Biological</b>		
Safe for human consumption	GRAS, nontoxic	Various assays - bacterial toxicology assays, 3D tissues in vitro screening
Source/Sourcing	Consistent source, scalable	Composition analysis
		Viscometer, rheometry, dynamic mechanical analysis, differential calorimetry, thermal gravimetric analysis
Taste	Palatability, flavor- & aromatic- compounds (or as byproducts of cooking), Maillard reaction products (for sugar-based scaffolds), oxidation, stability	Tasting-panels, chromatography, GC/MS, TBARS assay
Nutrition	Metabolites, metals, sugars, amino acids, vitamins	Digestion, analysis via HPLC/MS, metal analysis
Cell and tissue compatibility	Surface chemistry, metabolites, physical structure, morphology	FTIR, NMR, SIMs Tissue mimics in vitro (oral cavity, stomach, intestine)
<b>Environmental</b>		
Sustainability	Water, land, energy footprint, greenhouse gas emissions related	Life-cycle assessment

	to production, synthesis, processing	
--	---	--

422

423

424 **Consumer Acceptance**

425

426 One of the major questions about cultured meat is whether consumers will buy it. Indeed,  
 427 consumer acceptance is a necessary component for cultured meat’s commercial success in  
 428 the short term, and for its ability to bring about societal benefits in the long term.

429

430 Survey data on this question is rather inconsistent, and is dependent on a number of factors  
 431 including the phrasing of the question and the nationality of the sample <sup>102,103</sup>. Table 3 shows  
 432 a summary of the results of nationally representative survey questions about cultured meat  
 433 to date.

434

435 **Table 3: A summary of nationally representative survey questions on cultured meat.**

436

Survey	Sample	Question	Would eat	Don’t know	Would not eat
YouGov (2013)	1,729 UK adults (18+)	“Imagine artificial meat was available commercially, do you think you would eat it?”	19%	19%	62%
Pew Research (2014)	1,001 USA adults (18+)	“Would you... Eat meat that was grown in a lab?”	20%	2%	78%
Flycatcher (2013)	1,296 Netherlands adults (18+)	“Suppose that cultured meat is available at the supermarket. Would you buy cultured meat in order to try it?”	52%	23%	25%

The Grocer (2017)	2,082 UK adults (16+)	“Would you ever buy ‘cultured meat’ grown in a laboratory?”	16%	33%	50%
Wilks and Phillips (2017)	673 USA adults (18+)	“Would you be willing to try <i>in vitro</i> meat?”	65%	12%	21%
Surveygoo (2018)	1,000 UK and USA adults (18+)	“Would you be willing to eat cultured meat?”	29%	38%	33%
Bryant et al. (2019)	3,030 USA, India, and China adults (18+)	“How likely are you to try clean meat?”	52%	34%	13%

437

438 Although samples and question wording surely affect survey responses, the main  
439 differences here appear to be based on the amount of information given to participants. The  
440 three most optimistic survey results come from longer, cultured meat focused, surveys that  
441 gave participants plenty of positive information <sup>103-105</sup>. The most negative results, meanwhile,  
442 come from surveys where participants are given very little information about cultured meat,  
443 often as part of a longer omnibus survey (Pew Research, 2014; The Grocer, 2017; YouGov,  
444 2013). Indeed, this explanation fits with the finding that positive (and negative) information  
445 about cultured meat influences attitudes in the direction of the information <sup>106</sup>.

446

447 Various experimental studies have demonstrated a number of ways in which acceptance of  
448 cultured meat can be increased. When cultured meat is primarily framed as a high-tech  
449 science innovation, it is significantly less appealing than when the focus is on its societal  
450 benefits or its similarity to conventional meat <sup>103</sup>. Similarly, overly technical descriptions are  
451 less appealing than more straightforward descriptions <sup>107</sup>, and names like ‘lab grown meat’  
452 which invoke science and unnaturalness are significantly less appealing than names like  
453 ‘clean meat’ which highlight the benefits relative to conventional meat <sup>102</sup>. Consumers are

454 also more likely to choose cultured meat when the price is lower, and when the perceived  
455 popularity amongst others is higher <sup>108</sup>.

456

457 Data shows that most Americans (57.3%) are 'not at all familiar' with cultured meat <sup>109</sup>.

458 Familiarity with the technology is a major predictor of acceptance whilst food neophobia is a  
459 major predictor of rejection (Bryant et al., 2019; <sup>110</sup>. Furthermore, focus groups on the topic  
460 have charted the course of initially negative attitudes towards cultured meat, which often  
461 become less negative after further consideration of the concept <sup>111,112</sup>. Therefore, despite a  
462 lack of meaningful longitudinal data, it is likely that attitudes and intentions towards cultured  
463 meat will become more positive as more people become aware of it and more familiar with  
464 the concept.

465

466 Various studies have found higher acceptance of cultured meat amongst men compared to  
467 women, amongst younger people compared to older people, and amongst omnivores  
468 compared to vegetarians <sup>104,105,108,109,111,113</sup>. Bryant and Barnett (2018) have argued that the  
469 gender disparity may relate to women having more cautious stances towards foods in  
470 general <sup>114</sup>, whilst the age trend is likely due to higher openness to new experience amongst  
471 younger people <sup>115</sup>.

472

473 The findings regarding vegetarianism are interesting - since cultured meat circumvents the  
474 primary ethical and environmental motivations for vegetarianism <sup>116</sup>, one might think that  
475 vegetarians should be no more likely to reject cultured meat than omnivores. However, it is  
476 common for vegetarians to acquire an emotional disgust reaction to meat in general, which  
477 may supersede rational reasons for avoiding meat <sup>117,118</sup>. The relative lack of appeal of  
478 cultured meat to vegetarians should not be a major concern for producers or advocates:  
479 those who avoid meat are a small fraction of the market, and are, in any case, not  
480 contributing to the problems of conventional meat production. Moreover, it is important for  
481 the long-term ability of cultured meat to displace demand for conventional meat that it does

482 not come to be seen as a product for vegetarians.

483

484 Experts anticipated that cultured meat would be more appealing to consumers in America  
485 and Asia compared to Europeans <sup>119</sup> and now data appears to bear this out. Whilst the  
486 British were amongst the most accepting of cultured meat in Europe in a 2005 survey <sup>120</sup>,  
487 they are substantially less accepting than their American cousins <sup>121</sup>. Americans, in turn, are  
488 less willing to eat cultured meat than those in China and India <sup>109</sup>. Such differences may be  
489 related to the different roles animal agriculture plays in these societies and cultures.

490


491 Of course, a major limitation of all the research on consumer acceptance of cultured meat is  
492 its hypothetical nature. Since there are no cultured meat products currently available  
493 commercially, researchers have been unable to observe the nature of consumer preferences  
494 in practice or explore specific aspects of the product which are appealing. However, as  
495 Bryant and Barnett (2018) observe, consumer perceptions of cultured meat are similar to  
496 perceptions of genetically modified food in terms of demographic trends <sup>102</sup>. Some  
497 consumers view these technologies as conceptually similar <sup>122</sup>, and attitudes are often  
498 underpinned by similar sets of concerns.

499

### 500 **Complex tissues**

501 Currently, most cultured meat tissues consist of muscle tissue only<sup>16</sup>, and minced meat  
502 products from muscle and fat are made by separately growing muscle fibres and adipose  
503 organoids to later be combined in the final meat product formulation. Meat is not only  
504 muscle, but a tissue composed of muscle, fat and connective tissue <sup>123</sup>, ideally mimicked by  
505 culturing a tissue with similar composition. To grow these different cells together in a single  
506 tissue, a more advanced tissue engineering approach is therefore needed(Ben-Arye,  
507 unpublished), <sup>124-126</sup> (Fig 3).

508



509

510 Figure 3: Production of complex meat products from muscle, fat, connective tissue and  
 511 vascular cells, using a scaffold method.

512

513 The advantage of culturing complex tissue is not only that the composition of the produced  
 514 tissue will better approximate regular meat, but also that mutual beneficial interactions  
 515 between different cell types can be leveraged. The minimal requirement for such a complex  
 516 tissue seems to be the presence of muscle fibers, adipose tissue, fibrous and vascular cells,  
 517 by combining their respective progenitor cells and differentiating them to their final,  
 518 functional, phenotype.

519 Evidence of beneficial interactions between vascular cells (endothelial cells: ECs) and  
 520 skeletal muscle and adipose tissue derived stem cells shows that ECs secrete growth  
 521 factors and cytokines promoting proliferation and differentiation of muscle progenitors into  
 522 fibres<sup>127</sup>, as well as promoting adipogenesis<sup>128</sup>. In addition, extracellular matrix components  
 523 (ECM) secreted by microvascular endothelial cells and fibroblasts stimulate preadipocyte

524 differentiation and muscle maturation, while providing texture to meat <sup>129-132</sup>. The most  
525 challenging component of this complex tissue is the adipose tissue, with little scientific  
526 evidence of applicability in cultured meat<sup>133</sup>. Currently adopted protocols to stimulate  
527 adipogenesis in human and murine cells are not suitable for generating edible tissue <sup>123</sup>.  
528 Thus, food compatible adipose tissue differentiation from common livestock animals should  
529 be established first, before addressing the challenge of combining fat cells with muscle cells.  
530 Co-culturing of different cells typically requires an elaborate optimization of growth medium  
531 and differentiation protocols <sup>134</sup>. The formation of a complex muscle tissue is also dictated by  
532 the properties of the scaffold biomaterial which, to be suitable for muscle and adipose tissue  
533 formation, it should be formulated to yield appropriate stiffness<sup>135</sup>, for both tissues <sup>136,137</sup>.  
534 However, adipose tissue requires low stiffness, whereas muscle tissue requires a higher  
535 one, a suitable combination might therefore be challenging.  
536 Formation of cultured muscle fibres and muscle contractility can be further promoted via  
537 mechanical and/or electric stimulation applied on the complex tissue construct <sup>138,139</sup>.  
538 Achieving muscle contractility presents an added value for cultured meat, as it stimulates  
539 muscle cell production of proteins such as myoglobin, which is responsible for the red color  
540 of meat and is an important source of iron <sup>140</sup>.

541

542 Finally, thickness is another aspect of engineered complex tissues. To create attractive meat  
543 analogues, instance thickness of 1 cm or more is needed. This scale is far beyond the  
544 diffusion limits of oxygen and nutrients. To prevent tissue from dying, a channelling and  
545 perfusion system that allows even and sufficient delivery of oxygen and nutrients and  
546 adequate effusion of metabolic waste, is required <sup>141,142</sup>. The channelling system could come  
547 from spontaneously assembling ECs into a network of blood vessels or from a printed  
548 hierarchical vascular tree as has been recently demonstrated at small scale <sup>143</sup>. The  
549 functionality of the artificial blood vessels may affect muscle maturation through paracrine  
550 interaction or may just be a conduit system. The channels or blood vessels likely do not  
551 contribute appreciably to the taste and texture of the cultured meat product. Cost effective

552 scaling up of whole thickness perfused engineered tissue is obviously a massive engineering  
553 challenge.

554

555 .

556

557

558

559

560

561

562

563

564

565

566

## 567 **References**

568

569

570 1 Sharma, S., Thind, S. S. & Kaur, A. In vitro meat production system: why and how? *J*

571 *Food Sci Technol* **52**, 7599-7607, doi:10.1007/s13197-015-1972-3 (2015).

572 2 Macdiarmid, J. I., Douglas, F. & Campbell, J. Eating like there's no tomorrow: Public

573 awareness of the environmental impact of food and reluctance to eat less meat as

574 part of a sustainable diet. *Appetite* **96**, 487-493, doi:10.1016/j.appet.2015.10.011

575 (2016).

576 3 Mattick, C. S., Landis, A. E., Allenby, B. R. & Genovese, N. J. Anticipatory Life Cycle

577 Analysis of In Vitro Biomass Cultivation for Cultured Meat Production in the United

578 States. *Environ Sci Technol* **49**, 11941-11949, doi:10.1021/acs.est.5b01614 (2015).

579 4 Tuomisto, H. L. & de Mattos, M. J. Environmental impacts of cultured meat

580 production. *Environ Sci Technol* **45**, 6117-6123, doi:10.1021/es200130u (2011).

581 5 Tuomisto, H. L., Ellis, M. J. & Haastруп, P. in *LCA Food 2014*. (eds R. Schenck & D.

582 Huizenga) (Vashon, WA, USA).

583 6 Lynch, J. & Pierrehumbert, R. Climate Impacts of Cultured Meat and Beef Cattle.

584 *Frontiers in Sustainable food systems* **3**, doi:10.3389/fsufs.2019.00005 (2019).

585 7 Schaefer, G. O. & Savulescu, J. The Ethics of Producing In Vitro Meat. *Journal of*

586 *Applied Philosophy* **31**, 188-202, doi:10.1111/japp.12056 (2014).

587 8 Reese, j. *US Factory Farming Estimates*, <[https://www.sentienceinstitute.org/us-](https://www.sentienceinstitute.org/us-factory-farming-estimates)

588 [factory-farming-estimates](https://www.sentienceinstitute.org/us-factory-farming-estimates)> (2019).

589 9 Mathew, A. G., Cissell, R. & Liamthong, S. Antibiotic Resistance in Bacteria

590 Associated with Food Animals: A United States Perspective of Livestock Production.

591 *Foodborne Pathogens and Disease* **4**, 115-133, doi:10.1089/fpd.2006.0066 (2007).

592 10 Oliver, S. P., Murinda, S. E. & Jayarao, M. Impact of Antibiotic Use in Adult Dairy

593 Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A

594 Comprehensive Review. *Foodborne Pathogens and Disease* **8**, 337-355,

595 doi:10.1089/fpd.2010.0730 (2011).

596 11 FAO. World Livestock 2011. Livestock in food security. *FAO publications* (2011).

597 12 Young, P. *The Victorians caused the meat eating crisis the world faces today - but*

598 *they might help us solve it*, <[http://theconversation.com/the-victorians-caused-the-](http://theconversation.com/the-victorians-caused-the-meat-eating-crisis-the-world-faces-today-but-they-might-help-us-solve-it-109310)

599 [meat-eating-crisis-the-world-faces-today-but-they-might-help-us-solve-it-109310](http://theconversation.com/the-victorians-caused-the-meat-eating-crisis-the-world-faces-today-but-they-might-help-us-solve-it-109310)>

600 (2019).

601 13 Post, M. J. Cultured beef: medical technology to produce food. *Journal of the science*

602 *of food and agriculture* **94**, 1039-1041, doi:10.1002/jsfa.6474 (2014).

603 14 Williams, L. A., Davis-Dusenbery, B. N. & Eggan, K. C. SnapShot: directed

604 differentiation of pluripotent stem cells. *Cell* **149**, 1174-1174 e1171,

605 doi:10.1016/j.cell.2012.05.015 (2012).

606 15 Diaz-Flores, L., Jr. *et al.* Adult stem and transit-amplifying cell location. *Histol*

607 *Histopathol* **21**, 995-1027, doi:10.14670/HH-21.995 (2006).

608 16 Post, M. J. Cultured meat from stem cells: challenges and prospects. *Meat Sci* **92**,  
609 297-301, doi:10.1016/j.meatsci.2012.04.008 (2012).

610 17 Stephens, N. *et al.* Bringing cultured meat to market: Technical, socio-political, and  
611 regulatory challenges in cellular agriculture. *Trends in Food Science & Technology*  
612 **78**, 155-166, doi:<https://doi.org/10.1016/j.tifs.2018.04.010> (2018).

613 18 Wosczyzna, M. N. & Rando, T. A. A Muscle Stem Cell Support Group: Coordinated  
614 Cellular Responses in Muscle Regeneration. *Developmental cell* **46**, 135-143,  
615 doi:10.1016/j.devcel.2018.06.018 (2018).

616 19 Post, M. J. & van der Weele, C. in *Principles of Tissue Engineering* (eds R. Lanza,  
617 R. Langer, & J. P. Vacanti) Ch. 78, 1647-1658 (Elsevier, 2014).

618 20 Zhu, H. *et al.* Porcine satellite cells are restricted to a phenotype resembling their  
619 muscle origin. *J Anim Sci* **91**, 4684-4691, doi:10.2527/jas.2012-5804 (2013).

620 21 Ding, S. *et al.* Maintaining bovine satellite cells stemness through p38 pathway. *Sci*  
621 *Rep* **8**, 11, doi:10.1038/s41598-018-28746-7 (2018).

622 22 Ding, S. *et al.* Characterization and isolation of highly purified porcine satellite cells.  
623 *Cell Death Discovery* **3**, 17003, doi:10.1038/cddiscovery.2017.3.  
624 <https://www.nature.com/articles/cddiscovery20173#supplementary-information>  
625 (2017).

626 23 Rouger, K. *et al.* Progenitor Cell Isolation from Muscle-derived Cells based on  
627 Adhesion Properties. *Journal of Histochemistry & Cytochemistry* **55**, 607-618,  
628 doi:10.1369/jhc.6A6954.2007 (2007).

629 24 Wilschut, K. J., Jaksani, S., Van Den Dolder, J., Haagsman, H. P. & Roelen, B. A. J.  
630 Isolation and characterization of porcine adult muscle-derived progenitor cells.  
631 *Journal of Cellular Biochemistry* **105**, 1228-1239, doi:10.1002/jcb.21921 (2008).

632 25 Specht, E. A., Welch, D. R., Rees Clayton, E. M. & Lagally, C. D. Opportunities for  
633 applying biomedical production and manufacturing methods to the development of  
634 the clean meat industry. *Biochemical Engineering Journal* **132**, 161-168,  
635 doi:<https://doi.org/10.1016/j.bej.2018.01.015> (2018).

- 636 26 van der Weele, C. & Tramper, J. Cultured meat: every village its own factory? *Trends*  
637 *Biotechnol* **32**, 294-296, doi:10.1016/j.tibtech.2014.04.009 (2014).
- 638 27 Yaffe, D. Retention of differentiation potentialities during prolonged cultivation of  
639 myogenic cells. *Proceedings of the National Academy of Sciences of the United*  
640 *States of America* **61**, 477-483, doi:10.1073/pnas.61.2.477 (1968).
- 641 28 Yaffe, D. & Saxel, O. R. A. Serial passaging and differentiation of myogenic cells  
642 isolated from dystrophic mouse muscle. *Nature* **270**, 725-727, doi:10.1038/270725a0  
643 (1977).
- 644 29 Antin, P. B. & Ordahl, C. P. Isolation and characterization of an avian myogenic cell  
645 line. *Developmental biology* **143**, 111-121, doi:[https://doi.org/10.1016/0012-](https://doi.org/10.1016/0012-1606(91)90058-B)  
646 [1606\(91\)90058-B](https://doi.org/10.1016/0012-1606(91)90058-B) (1991).
- 647 30 Zhu, C.-H. *et al.* Cellular senescence in human myoblasts is overcome by human  
648 telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in  
649 aging muscle and therapeutic strategies for muscular dystrophies. *Aging Cell* **6**, 515-  
650 523, doi:10.1111/j.1474-9726.2007.00306.x (2007).
- 651 31 Roberts, R. M., Yuan, Y., Genovese, N. & Ezashi, T. Livestock Models for Exploiting  
652 the Promise of Pluripotent Stem Cells. *ILAR Journal* **56**, 74-82, doi:10.1093/ilar/ilv005  
653 (2015).
- 654 32 Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse  
655 embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663-676,  
656 doi:S0092-8674(06)00976-7 [pii] 10.1016/j.cell.2006.07.024 (2006).
- 657 33 Bogliotti, Y. S. *et al.* Efficient derivation of stable primed pluripotent embryonic stem  
658 cells from bovine blastocysts. *Proceedings of the National Academy of Sciences* **115**,  
659 2090-2095, doi:10.1073/pnas.1716161115 (2018).
- 660 34 Choi, K.-H. *et al.* Chemically Defined Media Can Maintain Pig Pluripotency Network  
661 In Vitro. *Stem Cell Reports* **13**, 221-234,  
662 doi:<https://doi.org/10.1016/j.stemcr.2019.05.028> (2019).
- 663 35 Ezashi, T. *et al.* Derivation of induced pluripotent stem cells from pig somatic cells.

664 *Proc Natl Acad Sci U S A* **106**, 10993-10998, doi:0905284106 [pii]  
665 10.1073/pnas.0905284106 (2009).

666 36 Gao, X. *et al.* Establishment of porcine and human expanded potential stem cells.  
667 *Nature cell biology* **21**, 687-699, doi:10.1038/s41556-019-0333-2 (2019).

668 37 Pain, B., Kress, C. & Rival-Gervier, S. Pluripotency in avian species. *Int J Dev Biol*  
669 **62**, 245-255, doi:10.1387/ijdb.170322bp (2018).

670 38 Chal, J. & Pourquié, O. Making muscle: skeletal myogenesis *in vivo* and  
671 *in vitro*. *Development* **144**, 2104-2122, doi:10.1242/dev.151035 (2017).

672 39 Rao, L., Qian, Y., Khodabukus, A., Ribar, T. & Bursac, N. Engineering human  
673 pluripotent stem cells into a functional skeletal muscle tissue. *Nature*  
674 *Communications* **9**, 126, doi:10.1038/s41467-017-02636-4 (2018).

675 40 Genovese, N. J., Domeier, T. L., Telugu, B. P. V. L. & Roberts, R. M. Enhanced  
676 Development of Skeletal Myotubes from Porcine Induced Pluripotent Stem Cells.  
677 *Scientific Reports* **7**, 41833, doi:10.1038/srep41833.  
678 <https://www.nature.com/articles/srep41833#supplementary-information> (2017).

679 41 Ludwig, T. & Thomson, J. Defined, Feeder-Independent Medium for Human  
680 Embryonic Stem Cell Culture. *Current Protocols in Stem Cell Biology* **2**, 1C.2.1-  
681 1C.2.16, doi:10.1002/9780470151808.sc01c02s2 (2007).

682 42 Ying, Q.-L. *et al.* The ground state of embryonic stem cell self-renewal. *Nature* **453**,  
683 519, doi:10.1038/nature06968.  
684 <https://www.nature.com/articles/nature06968#supplementary-information> (2008).

685 43 Chen, G. *et al.* Chemically defined conditions for human iPSC derivation and culture.  
686 *Nature Methods* **8**, 424, doi:10.1038/nmeth.1593.  
687 <https://www.nature.com/articles/nmeth.1593#supplementary-information> (2011).

688 44 Burrell, K. *et al.* Stirred Suspension Bioreactor Culture of Porcine Induced Pluripotent  
689 Stem Cells. *bioRxiv*, 644195, doi:10.1101/644195 (2019).

690 45 Manstein, F., Halloin, C. & Zweigerdt, R. in *Cell-Based Assays Using iPSCs for Drug*  
691 *Development and Testing* (eds Carl-Fredrik Mandenius & James A. Ross) 79-91

692 (Springer New York, 2019).

693 46 Mizukami, A. & Swiech, K. Mesenchymal Stromal Cells: From Discovery to  
694 Manufacturing and Commercialization. *Stem cells international* **2018**, 4083921,  
695 doi:10.1155/2018/4083921 (2018).

696 47 Amable, P. & Butler, M. in *Animal Cell Technology* (eds L. Castilho, A. Moraes, E.  
697 Augusta, & M. Butler) Ch. 4, 36 (Taylor & Francis, 2008).

698 48 Altamirano, C., Illanes, A., Becerra, S., Cairo, J. J. & Godia, F. Considerations on the  
699 lactate consumption by CHO cells in the presence of galactose. *J Biotechnol* **125**,  
700 547-556, doi:10.1016/j.jbiotec.2006.03.023 (2006).

701 49 Europa, A. F., Gambhir, A., Fu, P.-C. & Hu, W.-S. Multiple steady states with distinct  
702 cellular metabolism in continuous culture of mammalian cells. *Biotechnology and*  
703 *bioengineering* **67**, 25-34, doi:10.1002/(sici)1097-0290(20000105)67:1<25::Aid-  
704 bit4>3.0.Co;2-k (2000).

705 50 Bell, S. L. *et al.* Genetic engineering of hybridoma glutamine metabolism. *Enzyme*  
706 *and Microbial Technology* **17**, 98-106, doi:[https://doi.org/10.1016/0141-](https://doi.org/10.1016/0141-0229(94)00056-W)  
707 [0229\(94\)00056-W](https://doi.org/10.1016/0141-0229(94)00056-W) (1995).

708 51 Bell, S. L. *et al.* in *Animal Cell Technology* (eds R. E. Spier, J. B. Griffiths, & C.  
709 MacDonald) 180-182 (Butterworth-Heinemann, 1992).

710 52 Weidemann, R., Ludwig, A. & Kretzmer, G. Low temperature cultivation — A step  
711 towards process optimisation. *Cytotechnology* **15**, 111-116, doi:10.1007/bf00762385  
712 (1994).

713 53 Hulland, T. J. in *Pathology of Domestic Animals (Fourth Edition)* (eds K. V. F. Jubb,  
714 Peter C. Kennedy, & Nigel Palmer) 183-265 (Academic Press, 1993).

715 54 Lindholm, A., Johansson, H. E. & Kjaersgaard, P. Acute rhabdomyolysis ("tying-up")  
716 in standardbred horses. A morphological and biochemical study. *Acta Vet Scand* **15**,  
717 14 (1974).

718 55 McLean, J. G. EQUINE PARALYTIC MYOGLOBINURIA ("AZOTURIA"): A REVIEW\*.  
719 *Australian Veterinary Journal* **49**, 41-43, doi:10.1111/j.1751-0813.1973.tb14679.x

720 (1973).

721 56 Goedegebuure, S. A. Spontaneous primary myopathies in domestic mammals: a  
722 review. *Veterinary Quarterly* **9**, 16 (1987).

723 57 Ryan, P. A., Maher, V. M. & McCormick, J. J. Modification of MCDB 110 medium to  
724 support prolonged growth and consistent high cloning efficiency of diploid human  
725 fibroblasts. *Experimental Cell Research* **172**, 318-328,  
726 [doi:https://doi.org/10.1016/0014-4827\(87\)90390-9](https://doi.org/10.1016/0014-4827(87)90390-9) (1987).

727 58 Braga, M., Simmons, Z., Norris, K. C., Ferrini, M. G. & Artaza, J. N. Vitamin D  
728 induces myogenic differentiation in skeletal muscle derived stem cells. *Endocr*  
729 *Connect* **6**, 139-150, doi:10.1530/EC-17-0008 (2017).

730 59 Ikeda, M. & Nakagawa, S. The *Corynebacterium glutamicum* genome: features and  
731 impacts on biotechnological processes. *Applied Microbiology and Biotechnology* **62**,  
732 99-109, doi:10.1007/s00253-003-1328-1 (2003).

733 60 Vercalsteren, A. & Boonen, K. Life Cycle Assessment study of starch products for the  
734 European starch industry association (Starch Europe): sector study. (the European  
735 starch industry association, Boeretang, 2015).

736 61 Kim, S.-K. *Marine Proteins and Peptides: Biological Activities and Applications*.  
737 (Wiley-Blackwell, 2013).

738 62 Matassa, S., Verstraete, W., Pikaar, I. & Boon, N. Autotrophic nitrogen assimilation  
739 and carbon capture for microbial protein production by a novel enrichment of  
740 hydrogen-oxidizing bacteria. *Water Research* **101**, 137-146,  
741 [doi:https://doi.org/10.1016/j.watres.2016.05.077](https://doi.org/10.1016/j.watres.2016.05.077) (2016).

742 63 Nasser, A. T., Rasoul-Amini, S., Morowvat, M. H. & Ghasemi, Y. Single Cell Protein:  
743 Production and Process. *Journal of Food Technology* **6**, 13 (2011).

744 64 Ramos Tercero, E. A., Sforza, E., Morandini, M. & Bertucco, A. Cultivation of  
745 *Chlorella protothecoides* with Urban Wastewater in Continuous Photobioreactor:  
746 Biomass Productivity and Nutrient Removal. *Applied Biochemistry and Biotechnology*  
747 **172**, 1470-1485, doi:10.1007/s12010-013-0629-9 (2014).

748 65 Xu, H., Miao, X. & Wu, Q. High quality biodiesel production from a microalga  
749 *Chlorella protothecoides* by heterotrophic growth in fermenters. *Journal of*  
750 *Biotechnology* **126**, 499-507, doi:<https://doi.org/10.1016/j.jbiotec.2006.05.002> (2006).

751 66 Lowrey, J., Armenta, R. E. & Brooks, M. S. Nutrient and media recycling in  
752 heterotrophic microalgae cultures. *Applied Microbiology and Biotechnology* **100**,  
753 1061-1075, doi:10.1007/s00253-015-7138-4 (2016).

754 67 Yang, L. *et al.* A novel low cost microalgal harvesting technique with coagulant  
755 recovery and recycling. *Bioresource Technology* **266**, 343-348,  
756 doi:<https://doi.org/10.1016/j.biortech.2018.06.105> (2018).

757 68 Zhu, C., Zhang, R., Cheng, L. & Chi, Z. A recycling culture of *Neochloris*  
758 *oleoabundans* in a bicarbonate-based integrated carbon capture and algae  
759 production system with harvesting by auto-flocculation. *Biotechnology for Biofuels* **11**,  
760 204, doi:10.1186/s13068-018-1197-6 (2018).

761 69 Khodayari, A. & Maranas, C. D. A genome-scale *Escherichia coli* kinetic metabolic  
762 model k-ecoli457 satisfying flux data for multiple mutant strains. *Nature*  
763 *Communications* **7**, 13806, doi:10.1038/ncomms13806.  
764 <https://www.nature.com/articles/ncomms13806#supplementary-information> (2016).

765 70 Mannan, A. A. *et al.* Integrating Kinetic Model of *E. coli* with Genome Scale Metabolic  
766 Fluxes Overcomes Its Open System Problem and Reveals Bistability in Central  
767 Metabolism. *PLoS one* **10**, e0139507, doi:10.1371/journal.pone.0139507 (2015).

768 71 Reed, L. K., Baer, C. F. & Edison, A. S. Considerations when choosing a genetic  
769 model organism for metabolomics studies. *Current Opinion in Chemical Biology* **36**,  
770 7-14, doi:<https://doi.org/10.1016/j.cbpa.2016.12.005> (2017).

771 72 Fuhrer, T., Zampieri, M., Sévin, D. C., Sauer, U. & Zamboni, N. Genomewide  
772 landscape of gene–metabolome associations in *Escherichia coli*. *Molecular Systems*  
773 *Biology* **13**, 907, doi:10.15252/msb.20167150 (2017).

774 73 Birch, E. W., Udell, M. & Covert, M. W. Incorporation of flexible objectives and time-  
775 linked simulation with flux balance analysis. *Journal of Theoretical Biology* **345**, 12-

776 21, doi:<https://doi.org/10.1016/j.jtbi.2013.12.009> (2014).

777 74 Feist, A. M. & Palsson, B. O. What do cells actually want? *Genome Biol* **17**, 110-110,  
778 doi:10.1186/s13059-016-0983-3 (2016).

779 75 Parker, G. A. & Smith, J. M. Optimality theory in evolutionary biology. *Nature* **348**, 27-  
780 33, doi:10.1038/348027a0 (1990).

781 76 Vijayakumar, S., Conway, M., Lió, P. & Angione, C. in *Metabolic Network*  
782 *Reconstruction and Modeling: Methods and Protocols* (ed Marco Fondi) 389-408  
783 (Springer New York, 2018).

784 77 Zakrzewski, P. *et al.* MultiMetEval: Comparative and Multi-Objective Analysis of  
785 Genome-Scale Metabolic Models. *PloS one* **7**, e51511,  
786 doi:10.1371/journal.pone.0051511 (2012).

787 78 Heng, B. C. *et al.* Effect of cell-seeding density on the proliferation and gene  
788 expression profile of human umbilical vein endothelial cells within ex vivo culture.  
789 *Cytotherapy* **13**, 606-617, doi:10.3109/14653249.2010.542455 (2011).

790 79 Larson, B. L., Ylostalo, J. & Prockop, D. J. Human multipotent stromal cells undergo  
791 sharp transition from division to development in culture. *Stem Cells* **26**, 193-201,  
792 doi:10.1634/stemcells.2007-0524 (2008).

793 80 Moritz, M. S. M., Verbruggen, S. E. L. & Post, M. J. Alternatives for large-scale  
794 production of cultured beef: A review. *Journal of Integrative Agriculture* **14**, 208-216,  
795 doi:[https://doi.org/10.1016/S2095-3119\(14\)60889-3](https://doi.org/10.1016/S2095-3119(14)60889-3) (2015).

796 81 Verbruggen, S., Luining, D., van Essen, A. & Post, M. J. Bovine myoblast cell  
797 production in a microcarriers-based system. *Cytotechnology* **70**, 503-512,  
798 doi:10.1007/s10616-017-0101-8 (2018).

799 82 Lipsitz, Y. Y., Woodford, C., Yin, T., Hanna, J. H. & Zandstra, P. W. Modulating cell  
800 state to enhance suspension expansion of human pluripotent stem cells.  
801 *Proceedings of the National Academy of Sciences* **115**, 6369,  
802 doi:10.1073/pnas.1714099115 (2018).

803 83 Fok, E. Y. & Zandstra, P. W. Shear-controlled single-step mouse embryonic stem cell

804 expansion and embryoid body-based differentiation. *Stem Cells* **23**, 1333-1342,  
805 doi:10.1634/stemcells.2005-0112 (2005).

806 84 Abbasalizadeh, S., Larijani, M. R., Samadian, A. & Baharvand, H. Bioprocess  
807 development for mass production of size-controlled human pluripotent stem cell  
808 aggregates in stirred suspension bioreactor. *Tissue Engineering Part C: Methods* **18**,  
809 831-851 (2012).

810 85 Chen, V. C. *et al.* Scalable GMP compliant suspension culture system for human ES  
811 cells. *Stem Cell Res* **8**, 388-402, doi:10.1016/j.scr.2012.02.001 (2012).

812 86 Tsai, A.-C., Liu, Y., Yuan, X., Chella, R. & Ma, T. Aggregation kinetics of human  
813 mesenchymal stem cells under wave motion. *Biotechnol J* **12**, 1600448,  
814 doi:10.1002/biot.201600448 (2017).

815 87 Rafiq, Q. A., Brosnan, K. M., Coopman, K., Nienow, A. W. & Hewitt, C. J. Culture of  
816 human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor.  
817 *Biotechnology letters* **35**, 1233-1245 (2013).

818 88 Simaria, A. S. *et al.* Allogeneic cell therapy bioprocess economics and optimization:  
819 single-use cell expansion technologies. *Biotechnology and bioengineering* **111**, 69-  
820 83, doi:10.1002/bit.25008 (2014).

821 89 Schnitzler, A. C. *et al.* Bioprocessing of human mesenchymal stem/stromal cells for  
822 therapeutic use: Current technologies and challenges. *Biochemical Engineering*  
823 *Journal* **108**, 3-13, doi:<https://doi.org/10.1016/j.bej.2015.08.014> (2016).

824 90 Stephenson, M. & Grayson, W. Recent advances in bioreactors for cell-based  
825 therapies. *F1000Res* **7**, doi:10.12688/f1000research.12533.1 (2018).

826 91 Morrow, D., Ussi, A. & Migliaccio, G. Addressing Pressing Needs in the Development  
827 of Advanced Therapies. *Front Bioeng Biotechnol* **5**, 55,  
828 doi:10.3389/fbioe.2017.00055 (2017).

829 92 Moutsatsou, P., Ochs, J., Schmitt, R. H., Hewitt, C. J. & Hanga, M. P. Automation in  
830 cell and gene therapy manufacturing: from past to future. *Biotechnology letters* **41**,  
831 1245-1253, doi:10.1007/s10529-019-02732-z (2019).

- 832 93 Karageorgiou, V. & Kaplan, D. Porosity of 3D biomaterial scaffolds and osteogenesis.  
833 *Biomaterials* **26**, 5474-5491, doi:10.1016/j.biomaterials.2005.02.002 (2005).
- 834 94 Owen, S. C. & Shoichet, M. S. Design of three-dimensional biomimetic scaffolds.  
835 *Journal of biomedical materials research. Part A* **94**, 1321-1331,  
836 doi:10.1002/jbm.a.32834 (2010).
- 837 95 O'Brien, J. A. *et al.* Long-term histologic and mechanical results of a Permacol  
838 abdominal wall explant. *Hernia* **15**, 211-215, doi:10.1007/s10029-010-0628-5 (2011).
- 839 96 Garg, T. & Goyal, A. K. Biomaterial-based scaffolds--current status and future  
840 directions. *Expert Opin Drug Deliv* **11**, 767-789, doi:10.1517/17425247.2014.891014  
841 (2014).
- 842 97 Aamodt, J. M. & Grainger, D. W. Extracellular matrix-based biomaterial scaffolds and  
843 the host response. *Biomaterials* **86**, 68-82, doi:10.1016/j.biomaterials.2016.02.003  
844 (2016).
- 845 98 Cunha, A. G. & Gandini, A. Turning polysaccharides into hydrophobic materials: a  
846 critical review. Part 2. Hemicelluloses, chitin/chitosan, starch, pectin and alginates.  
847 *Cellulose* **17**, 1045-1065, doi:10.1007/s10570-010-9435-5 (2010).
- 848 99 Bugnicourt, E., Cinelli, P., Lazzeri, A. & Alvarez, V. A. Polyhydroxyalkanoate (PHA):  
849 Review of synthesis, characteristics, processing and potential applications in  
850 packaging. *eXPRESS Polymer Letters* **8**, 17, doi:10.3144/expresspolymlett.2014.82  
851 (2014).
- 852 100 Modulevsky, D. J., Lefebvre, C., Haase, K., Al-Rekabi, Z. & Pelling, A. E. Apple  
853 Derived Cellulose Scaffolds for 3D Mammalian Cell Culture. *PloS one* **9**, e97835,  
854 doi:10.1371/journal.pone.0097835 (2014).
- 855 101 de Boer, A. & Bast, A. Demanding safe foods – Safety testing under the novel food  
856 regulation (2015/2283). *Trends in Food Science & Technology* **72**, 125-133,  
857 doi:<https://doi.org/10.1016/j.tifs.2017.12.013> (2018).
- 858 102 Bryant, C. & Barnett, J. Consumer acceptance of cultured meat: A systematic review.  
859 *Meat Sci* **143**, 8-17, doi:10.1016/j.meatsci.2018.04.008 (2018).

- 860 103 Bryant, C. & Dillard, C. The Impact of Framing on Acceptance of Cultured Meat.  
861 *Front Nutr* **6**, 103, doi:10.3389/fnut.2019.00103 (2019).
- 862 104 Wilks, M. & Phillips, C. J. Attitudes to in vitro meat: A survey of potential consumers  
863 in the United States. *PloS one* **12**, e0171904, doi:10.1371/journal.pone.0171904  
864 (2017).
- 865 105 Flycatcher. *Dutch People wouldn't mind trying the "cultivated burger"*,  
866 <<https://www.flycatcher.eu/en/Home/NieuwsItem/38>> (2017).
- 867 106 Bekker, G. A., Fischer, A. R. H., Tobi, H. & van Trijp, H. C. M. Explicit and implicit  
868 attitude toward an emerging food technology: The case of cultured meat. *Appetite*  
869 **108**, 245-254, doi:<https://doi.org/10.1016/j.appet.2016.10.002> (2017).
- 870 107 Siegrist, M., Sütterlin, B. & Hartmann, C. Perceived naturalness and evoked disgust  
871 influence acceptance of cultured meat. *Meat Sci* **139**, 213-219,  
872 doi:<https://doi.org/10.1016/j.meatsci.2018.02.007> (2018).
- 873 108 Slade, P. If you build it, will they eat it? Consumer preferences for plant-based and  
874 cultured meat burgers. *Appetite* **125**, 428-437,  
875 doi:<https://doi.org/10.1016/j.appet.2018.02.030> (2018).
- 876 109 Bryant, C., Szejda, K., Parekh, N., Desphande, V. & Tse, B. A Survey of Consumer  
877 Perceptions of Plant-Based and Clean Meat in the USA, India, and China. *Frontiers*  
878 *in Sustainable Food Systems* **3**, 11, doi:10.3389/fsufs.2019.00011 (2019).
- 879 110 Wilks, M., Phillips, C. J. C., Fielding, K. & Hornsey, M. J. Testing potential  
880 psychological predictors of attitudes towards cultured meat. *Appetite* **136**, 137-145,  
881 doi:<https://doi.org/10.1016/j.appet.2019.01.027> (2019).
- 882 111 Tucker, C. A. The significance of sensory appeal for reduced meat consumption.  
883 *Appetite* **81**, 168-179, doi:10.1016/j.appet.2014.06.022 (2014).
- 884 112 Verbeke, W., Sans, P. & Van Loo, E. J. Challenges and prospects for consumer  
885 acceptance of cultured meat. *Journal of Integrative Agriculture* **14**, 285-294,  
886 doi:[https://doi.org/10.1016/S2095-3119\(14\)60884-4](https://doi.org/10.1016/S2095-3119(14)60884-4) (2015).
- 887 113 Tatum, M. *Meat the future... and how to market it*,

888 <http://www.thegrocer.co.uk/buying-and-supplying/categories/meat/meat-the-future->  
889 [and-how-to-market-it/546754.article](http://www.thegrocer.co.uk/buying-and-supplying/categories/meat/meat-the-future-and-how-to-market-it/546754.article) > (2017).

890 114 Backstrom, A., Pirttila-Backman, A. M. & Tuorila, H. Dimensions of novelty: a social  
891 representation approach to new foods. *Appetite* **40**, 299-307 (2003).

892 115 McCrae, R. R. *et al.* Age differences in personality across the adult life span:  
893 parallels in five cultures. *Dev Psychol* **35**, 466-477 (1999).

894 116 Lea, E. & Worsley, A. Benefits and barriers to the consumption of a vegetarian diet in  
895 Australia. *Public Health Nutr* **6**, 505-511, doi:10.1079/PHN2002452 (2003).

896 117 Rozin, P., Markwith, M. & Stoess, C. Moralization and Becoming a Vegetarian: The  
897 Transformation of Preferences Into Values and the Recruitment of Disgust.  
898 *Psychological Science* **8**, 67-73, doi:10.1111/j.1467-9280.1997.tb00685.x (1997).

899 118 Fessler, D. M. T., Arguello, A. P., Mekdara, J. M. & Macias, R. Disgust sensitivity and  
900 meat consumption: a test of an emotivist account of moral vegetarianism. *Appetite*  
901 **41**, 31-41, doi:[https://doi.org/10.1016/S0195-6663\(03\)00037-0](https://doi.org/10.1016/S0195-6663(03)00037-0) (2003).

902 119 Mattick, C. S., Wetmore, J. M. & Allenby, B. R. An Anticipatory Social Assessment of  
903 Factory-Grown Meat. *IEEE Technology and Society Magazine* **34**, 56-64,  
904 doi:10.1109/MTS.2015.2395967 (2015).

905 120 Commission, E. Social values. Science and Technology., 98 (EU Commission,  
906 Brussels, 2005).

907 121 Surveygoo. *Nearly one in three consumers willing to eat lab-grown meat, according*  
908 *to new research*, [https://www.datasmoothie.com/@surveygoo/nearly-one-in-three-](https://www.datasmoothie.com/@surveygoo/nearly-one-in-three-consumers-willing-to-eat-lab-g/)  
909 [consumers-willing-to-eat-lab-g/](https://www.datasmoothie.com/@surveygoo/nearly-one-in-three-consumers-willing-to-eat-lab-g/) > (2018).

910 122 Marcu, A. *et al.* Analogies, metaphors, and wondering about the future: Lay sense-  
911 making around synthetic meat. *Public Understanding of Science* **24**, 547-562,  
912 doi:10.1177/0963662514521106 (2015).

913 123 Ben-Arye, T. & Levenberg, S. Tissue Engineering for Clean Meat Production.  
914 *Frontiers in Sustainable Food Systems* **3**, doi:10.3389/fsufs.2019.00046 (2019).

915 124 Koffler, J. *et al.* Improved vascular organization enhances functional integration of

916 engineered skeletal muscle grafts. *Proceedings of the National Academy of Sciences*  
917 **108**, 14789-14794, doi:10.1073/pnas.1017825108 (2011).

918 125 Perry, L., Flugelman, M. Y. & Levenberg, S. Elderly Patient-Derived Endothelial Cells  
919 for Vascularization of Engineered Muscle. *Molecular Therapy* **25**, 935-948,  
920 doi:<https://doi.org/10.1016/j.ymthe.2017.02.011> (2017).

921 126 Shandalov, Y. *et al.* An engineered muscle flap for reconstruction of large soft tissue  
922 defects. *Proceedings of the National Academy of Sciences* **111**, 6010-6015,  
923 doi:10.1073/pnas.1402679111 (2014).

924 127 Christov, C. *et al.* Muscle Satellite Cells and Endothelial Cells: Close Neighbors and  
925 Privileged Partners. *Molecular Biology of the Cell* **18**, 1397-1409,  
926 doi:10.1091/mbc.e06-08-0693 (2007).

927 128 Guo, B. *et al.* Transcriptome analysis of cattle muscle identifies potential markers for  
928 skeletal muscle growth rate and major cell types. *BMC Genomics* **16**, 177,  
929 doi:10.1186/s12864-015-1403-x (2015).

930 129 Cao, Y. Angiogenesis modulates adipogenesis and obesity. *J Clin Invest* **117**, 2362-  
931 2368, doi:10.1172/JCI32239 (2007).

932 130 Cao, Y. Angiogenesis and vascular functions in modulation of obesity, adipose  
933 metabolism, and insulin sensitivity. *Cell Metab* **18**, 478-489,  
934 doi:10.1016/j.cmet.2013.08.008 (2013).

935 131 Du, M., Wang, B., Fu, X., Yang, Q. & Zhu, M. J. Fetal programming in meat  
936 production. *Meat Sci* **109**, 40-47, doi:10.1016/j.meatsci.2015.04.010 (2015).

937 132 Varzaneh, F. E., Shillabeer, G., Wong, K. L. & Lau, D. C. W. Extracellular matrix  
938 components secreted by microvascular endothelial cells stimulate preadipocyte  
939 differentiation in vitro. *Metabolism* **43**, 906-912, doi:[https://doi.org/10.1016/0026-](https://doi.org/10.1016/0026-0495(94)90275-5)  
940 [0495\(94\)90275-5](https://doi.org/10.1016/0026-0495(94)90275-5) (1994).

941 133 Mehta, F., Theunissen, R. & Post, M. J. in *Methods Mol Biol* Vol. 1889 111-125  
942 (2019).

943 134 Pullens, R. A., Stekelenburg, M., Baaijens, F. P. & Post, M. J. The influence of

944 endothelial cells on the ECM composition of 3D engineered cardiovascular  
945 constructs. *Journal of tissue engineering and regenerative medicine* **3**, 11-18 (2009).

946 135 Levy-Mishali, M., Zoldan, J. & Levenberg, S. Effect of scaffold stiffness on myoblast  
947 differentiation. *Tissue Eng Part A* **15**, 935-944, doi:10.1089/ten.tea.2008.0111  
948 (2009).

949 136 Comley, K. & Fleck, N. A. The toughness of adipose tissue: measurements and  
950 physical basis. *Journal of biomechanics* **43**, 1823-1826,  
951 doi:10.1016/j.jbiomech.2010.02.029 (2010).

952 137 Swift, J. *et al.* Nuclear lamin-A scales with tissue stiffness and enhances matrix-  
953 directed differentiation. *Science* **341**, 1240104, doi:10.1126/science.1240104 (2013).

954 138 Boonen, K. J. *et al.* Effects of a combined mechanical stimulation protocol: Value for  
955 skeletal muscle tissue engineering. *Journal of biomechanics* **43**, 1514-1521 (2010).

956 139 Powell, C. A., Smiley, B. L., Mills, J. & Vandenburg, H. H. Mechanical stimulation  
957 improves tissue-engineered human skeletal muscle. *American journal of physiology*  
958 **283**, C1557-1565, doi:10.1152/ajpcell.00595.2001 (2002).

959 140 Suman, S. P. & Joseph, P. Myoglobin Chemistry and Meat Color. *Annual Review of*  
960 *Food Science and Technology* **4**, 79-99, doi:10.1146/annurev-food-030212-182623  
961 (2013).

962 141 Post, M. J., Rahimi, N. & Caolo, V. Update on vascularization in tissue engineering.  
963 *Regenerative medicine* **8**, 759-770, doi:10.2217/rme.13.74 (2013).

964 142 Rouwkema, J., Rivron, N. C. & van Blitterswijk, C. A. Vascularization in tissue  
965 engineering. *Trends Biotechnol* **26**, 434-441, doi:10.1016/j.tibtech.2008.04.009  
966 (2008).

967 143 Grigoryan, B. *et al.* Multivascular networks and functional intravascular topologies  
968 within biocompatible hydrogels. *Science* **364**, 458-464, doi:10.1126/science.aav9750  
969 (2019).

970